Miami based eMed has secured $200 million in a Series A funding round, pushing its valuation above $2 billion. The round was led by AON Consulting with participation from Tom Brady, who serves as the company’s founding Chief Wellness Officer, along with other prominent investors including CEO Linda Yaccarino.
Glimpse:
Founded in 2020, eMed has evolved from its early focus on at home COVID-19 testing to a comprehensive population health platform. The fresh capital will help scale its empathic agentic AI platform, expand access to GLP-1 medications for obesity and diabetes management, and develop capitated care models tailored for employers to better control healthcare costs.
Miami based telehealth and AI startup eMed has successfully closed a $200 million Series A funding round, taking its valuation past the $2 billion mark. The company, which initially rose to prominence during the COVID-19 pandemic with at home testing solutions, has since transformed into a broader population health platform focused on chronic disease management and employer sponsored healthcare programs.
The latest investment round was led by AON Consulting and attracted several high-profile backers. These include NFL legend Tom Brady, who serves as eMed’s founding Chief Wellness Officer and has invested both capital and his time in the venture. Other participants include CEO Linda Yaccarino, Jeff Aronin, Ara Cohen, Antonio Gracias, Joe Lonsdale, R.J. Melman, and Tom Ricketts. The funds will primarily support the expansion of eMed’s AI-driven care delivery model and the rollout of new employer-focused programs.
At the heart of eMed’s platform is a combination of telehealth consultations, at-home diagnostics, and continuous clinical support. A major emphasis is placed on improving access to GLP-1 medications a class of drugs widely used for managing obesity and diabetes which are often limited by high costs and insurance restrictions. The company integrates medication access with ongoing monitoring and side effect management to create a complete care pathway rather than simply providing prescriptions. It has also strengthened its capabilities through acquisitions, including portions of Babylon’s UK telehealth operations, to enhance its preventive care offerings.
With this new capital, eMed aims to advance its capitated care model, helping employers more effectively manage healthcare expenses while increasing access to high demand therapies for chronic conditions. The startup is positioning itself at the intersection of advanced AI technology and employer led health benefits, with the goal of reshaping large scale management of chronic diseases.
“I believe eMed's empathic agentic AI platform, combined with the strength of its people and partners, represents a true winning formula. That conviction is why I've chosen to invest both my time as founding chief wellness officer and my capital in the company.”
By
HB Team
Related News
